Sub Banner Image

Perspective Therapeutics' Cancer-Focused Radiotherapy Portfolio Has Upside Potentional, Says Analyst

Biotech

Vandana Singh

·

March 13, 2025

·

Benzinga

H.C. Wainwright & Co. initiated coverage on Thursday for Perspective Therapeutics, Inc. (NASDAQ:CATX), a clinical-stage biotechnology company advancing “targeted radiotherapy agents” for cancer treatment.

Analyst Robert Burns initiated a Buy rating and a price target of $10.

The company’s pipeline comprises:

  • VMT01/02 for melanoma, which is being studied as both monotherapy and in combination with Opdivo (nivolumab).
  • VMT-α-NET for various neuroendocrine cancers and other SSTR2-expressing tumors.
  • PSV359 for multiple solid tumor types.
  • PSV40X for prostate cancer.

The company’s melanoma (VMT01) and neuroendocrine tumor (VMT-α-NET) programs have entered Phase 1/2a imaging and therapy trials for metastatic melanoma and neuroendocrine tumors.

Also Read: Positive Outlook For Novartis As Company Capitalizes On Growing Treatment Opportunities, Analyst Highlights

In January, Perspective Therapeutics revealed updated interim results from its ongoing Phase 1/2a trial of [212Pb]VMT-α-NET. Anti-tumor activities have been observed with a longer follow-up. As of the data cut-off date of Jan. 10, 2025, there were two unconfirmed responses and one confirmed response, as in Cohort 2.

H.C. Wainwright & Co. writes that from a safety perspective, 212Pb-VMT-α-NET appears to be relatively benign at the dose levels tested thus far.

The analyst writes that PSV359 and VMT01/02 constitute upside potential. Burns also notes that in preclinical experiments, VMT01/02 demonstrated high response rates in multiple tested models and >70% complete and durable response when combined with PD1 immunotherapy in a model highly resistant to checkpoint inhibitors

Perspective Therapeutics disclosed initial preclinical results for its FAPtargeted asset, PSV359 and views the preclinical anti-tumor efficacy as encouraging. The analyst also writes it is difficult to benchmark it against 177LuFAP-2286 and PNT6555 because these experiments were performed in a completely different mouse model.

“Additionally, when we think about potential targets for targeted radioligand therapy (TRT), we believe that most of the targets being pursued by ADCs and/or cell therapy are viable targets for TRT. As such, we view the targeted radioligand space as analogous to where the ADC space was a few years ago,” Burns writes.

Here are some M&A in the radiopharmaceutical therapeutics space:

  • In 2023, Bristol Myers Squibb & Co (NYSE:BMY) acquired RayzeBio for $62.50 per share in cash, for a total equity value of approximately $4.1 billion, or $3.6 billion net of estimated cash acquired
  • In 2023, Eli Lilly And Co (NYSE:LLY) acquired POINT Biopharma Global for $12.50 per share in cash, an aggregate of approximately $1.4 billion.
  • In 2024, AstraZeneca Plc (NASDAQ:AZN) acquired Fusion Pharmaceuticals for $21 per share in cash plus a non-transferable contingent value right of $3 per share in cash payable upon the achievement of a specified regulatory milestone.

CATX Price Action: Perspective Therapeutics stock is down 0.75% at $2.64 at publication Thursday.

Read Next:

Photo: S_fam photo via Shutterstock

More from

Benzinga

More

Biotech

Articles

Trending News

Enjoy premium content in your inbox.

You're in! Check your email to learn more.
Oops! Something went wrong while submitting the form.